{"id":15239,"date":"2026-07-09T13:42:00","date_gmt":"2026-07-09T08:12:00","guid":{"rendered":"https:\/\/mdforlives.com\/blog\/?p=15239"},"modified":"2026-07-09T13:42:00","modified_gmt":"2026-07-09T08:12:00","slug":"liquid-biopsy-cancer-recurrence","status":"publish","type":"post","link":"https:\/\/mdforlives.com\/blog\/liquid-biopsy-cancer-recurrence\/","title":{"rendered":"Can Liquid Biopsy Change Treatment Before Recurrence Is Visible?"},"content":{"rendered":"

What should an oncologist do when a blood test suggests recurrence, but the scan still shows nothing?<\/span>\u00a0<\/span><\/p>\n

That question is becoming one of the most important clinical tensions in modern oncology.<\/span>\u00a0<\/span><\/p>\n

Liquid biopsy, particularly circulating tumor DNA or ctDNA-based MRD testing, is changing what clinicians can see after curative-intent treatment. It can detect molecular signs of residual disease before recurrence becomes visible on imaging. In theory, that creates a powerful window: identify relapse earlier, intervene sooner, and potentially reshape surveillance or adjuvant treatment planning.<\/span>\u00a0<\/span><\/p>\n

But in real practice, earlier detection creates a harder question.<\/span>\u00a0<\/span><\/p>\n

Can you act before you see?<\/span>\u00a0<\/span><\/p>\n

The MDForLives insight reflects this exact gap. Across a global sample of oncologists, 58.1% report actively using ctDNA in practice. Nearly half, 48.4%, identify early detection of recurrence before imaging as its greatest benefit. Yet only 29.0% say ctDNA is already influencing treatment decisions in select cases.<\/span>\u00a0<\/span><\/p>\n

The pattern is clear: detection is ahead of decision.<\/span><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n